2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2017
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician 2017, 20: 353-362. PMID: 28727699.Peer-Reviewed Original ResearchConceptsEfficacy of palmitoylethanolamidePlacebo-controlled trialInactive control conditionsSystematic reviewVisual analog pain scaleAnalog pain scaleSerious adverse eventsEffect of palmitoylethanolamideWeighted mean differenceGreater pain reductionPEA treatmentInactive control groupPain reductionPain scoresAdverse eventsPain scalePain managementPrimary outcomeChronic painConcomitant treatmentControl conditionUseful treatmentAnalgesic agentsPlacebo controlClinical trials